These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 17132971

  • 1. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group.
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [Abstract] [Full Text] [Related]

  • 2. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.
    Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Memantine MEM-MD-02 Study Group.
    Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970
    [Abstract] [Full Text] [Related]

  • 3. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.
    Neurology; 2007 Jul 31; 69(5):459-69. PubMed ID: 17664405
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun 31; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 5. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group.
    JAMA; 2004 Jan 21; 291(3):317-24. PubMed ID: 14734594
    [Abstract] [Full Text] [Related]

  • 6. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P, Bladström A, Stender K.
    Int J Geriatr Psychiatry; 2009 May 21; 24(5):532-8. PubMed ID: 19274640
    [Abstract] [Full Text] [Related]

  • 7. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 May 21; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 8. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C.
    Issues Emerg Health Technol; 2005 Mar 21; (64):1-4. PubMed ID: 15762015
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC, Hoffman Snyder CR, Wellik KE, Caselli RJ, Wingerchuk DM, Demaerschalk BM.
    Neurologist; 2011 Mar 21; 17(2):121-3. PubMed ID: 21364371
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007 Mar 21; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

  • 11. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P.
    Int J Geriatr Psychiatry; 2008 Sep 21; 23(9):979-81. PubMed ID: 18229874
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.
    Curr Med Res Opin; 2007 Dec 21; 23(12):3153-65. PubMed ID: 17988434
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Takase T, Ohbayashi T.
    Dement Geriatr Cogn Disord; 2009 Dec 21; 27(3):232-9. PubMed ID: 19246907
    [Abstract] [Full Text] [Related]

  • 14. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.
    van Dyck CH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group.
    Am J Geriatr Psychiatry; 2006 May 21; 14(5):428-37. PubMed ID: 16670247
    [Abstract] [Full Text] [Related]

  • 15. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N, Ott BR, Peskind E, Resnick EM.
    Alzheimer Dis Assoc Disord; 2007 May 21; 21(1):60-4. PubMed ID: 17334274
    [Abstract] [Full Text] [Related]

  • 16. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R.
    J Med Econ; 2009 Jun 21; 12(2):98-103. PubMed ID: 19492974
    [Abstract] [Full Text] [Related]

  • 17. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.
    Curr Med Res Opin; 2005 Aug 21; 21(8):1317-27. PubMed ID: 16083542
    [Abstract] [Full Text] [Related]

  • 18. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
    Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S.
    Alzheimers Dement; 2009 Sep 21; 5(5):369-74. PubMed ID: 19751915
    [Abstract] [Full Text] [Related]

  • 19. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar 21; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 20. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.
    van Dyck CH, Tariot PN, Meyers B, Malca Resnick E, Memantine MEM-MD-01 Study Group.
    Alzheimer Dis Assoc Disord; 2007 Mar 21; 21(2):136-43. PubMed ID: 17545739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.